Literature DB >> 28663575

New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials.

P Moreau1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28663575     DOI: 10.1038/leu.2017.188

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Authors:  Jesús F San-Miguel; Paul G Richardson; Andreas Günther; Orhan Sezer; David Siegel; Joan Bladé; Richard LeBlanc; Heather Sutherland; Monika Sopala; Kaushal K Mishra; Song Mu; Priscille M Bourquelot; María Victoria Mateos; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

2.  Multiple myeloma--translation of trial results into reality.

Authors:  Philippe Moreau; S Vincent Rajkumar
Journal:  Lancet       Date:  2016-07-09       Impact factor: 79.321

Review 3.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

4.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

Review 5.  Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Authors:  J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 6.  Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.

Authors:  Jean-Samuel Boudreault; Cyrille Touzeau; Philippe Moreau
Journal:  Expert Rev Hematol       Date:  2017-02-09       Impact factor: 2.929

7.  Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Authors:  Jatin J Shah; Edward A Stadtmauer; Rafat Abonour; Adam D Cohen; William I Bensinger; Cristina Gasparetto; Jonathan L Kaufman; Suzanne Lentzsch; Dan T Vogl; Christina L Gomes; Natalia Pascucci; David D Smith; Robert Z Orlowski; Brian G M Durie
Journal:  Blood       Date:  2015-09-17       Impact factor: 22.113

8.  Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Authors:  Rachid C Baz; Thomas G Martin; Hui-Yi Lin; Xiuhua Zhao; Kenneth H Shain; Hearn J Cho; Jeffrey L Wolf; Anuj Mahindra; Ajai Chari; Daniel M Sullivan; Lisa A Nardelli; Kenneth Lau; Melissa Alsina; Sundar Jagannath
Journal:  Blood       Date:  2016-03-01       Impact factor: 22.113

Review 9.  Pomalidomide in the management of relapsed multiple myeloma.

Authors:  Cyrille Touzeau; Philippe Moreau
Journal:  Future Oncol       Date:  2016-06-10       Impact factor: 3.404

10.  Spotlight on pomalidomide: could less be more?

Authors:  T Zander; S Aebi; T Pabst; C Renner; C Driessen
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.